BioHedge Weekly
13D/13G filings from 18 institutional investors, cross-referenced with trial events and regulatory filings. Part of the RxDataLab platform with clinical trials, SEC filings, and hedge fund positioning, linked by company.
Weekly Filing Volume
Filings This Week
| Company | Fund | Ownership | Type |
|---|---|---|---|
| Relay Therapeutics, Inc. (RLAY) | Perceptive Advisors | 5.3% | New 13G [SEC] |
| Solid Biosciences Inc. (SLDB) | RA Capital Management | 9.9% | 13D/A [SEC] |
| Acumen Pharmaceuticals, Inc. (ABOS) | RA Capital Management | 29.5% ↑4.7 | 13D/A [SEC] |
| Vor Biopharma Inc. (VOR) | RA Capital Management | 19.9% ↑5.9 | 13D/A [SEC] |
New Positions
Funds disclosing >5% ownership in a company for the first time.
| Company | Fund | Ownership | Type |
|---|---|---|---|
| Relay Therapeutics, Inc. (RLAY) | Perceptive Advisors | 5.3% | SC 13G [SEC] |
About This Data
Schedule 13D/13G filings are SEC disclosures that report beneficial ownership. They are required when an investor acquires more than 5% of a company's shares. Schedule 13D filings indicate activist intent (potential influence over company direction), while 13G filings indicate passive investment.
New positions are filings where a fund discloses >5% ownership in a company for the first time.
We track 18 biotech-focused institutional investors with known sector expertise.
Data from RxDataLab and the SEC.